Skip to main content
. 2019 Apr 17;12:893–903. doi: 10.2147/IDR.S199759

Table 2.

Overall prevalence of antimicrobial resistance among five major sequence types (STs)

ST69 ST73 ST95 ST127 ST131
Antibiotics Insusceptible isolates, n (%)
Imipenem 0 2 (15.4) 2 (13.3) 0 2 (2.6)
Meropenem 0 1 (7.7) 1 (6.7) 0 1 (1.3)
Ertapenem 0 3 (23.1) 2 (13.3) 1 (4.5) 10 (13)
Ceftazidime 8 (33.3) 2 (15.4) 4 (26.7) 4 (18.2) 59 (76.6)
P-valuea 0.008 0.05 0.001 0.0001
Cefepime 2 (8.3) 3 (23.1) 0 4 (18.2) 45 (58.4)
P-value 0.002 0.001 0.0001
Cefotaxime 9 (37.5) 6 (46.2) 7 (46.7) 10 (45.5) 71 (92.2)
P-value 0.001 0.02 0.0001
Aztreonam 9 (37.5) 4 (30.8) 5 (33.3) 6 (27.3) 68 (88.3)
P-value 0.01 0.03 0.02 0.001 0.0001
Amoxicillin–clavulanate 12 (50) 5 (38.5) 4 (26.7) 11 (50) 46 (59.7)
P-value 0.05 0.05
Piperacillin–tazobactam 1 (4.2) 2 (15.4) 3 (20) 2 (9.1) 13 (16.9)
Ampicillin–sulbactam 2 (8.3) 5 (38.5) 3 (20) 5 (22.7) 34 (44.2)
P-value 0.004 0.002
Trimethoprim–sulfamethoxazole 22 (91.7) 7 (53.8) 5 (33.3) 8 (36.4) 53 (68.8)
P-value 0.001 0.02 0.008
Ciprofloxacin 5 (20.8) 4 (30.8) 5 (33.3) 5 (22.7) 69 (89.6)
P-value 0.0001 0.04 0.05 0.0001 0.0001
Levofloxacin 2 (8.3) 2 (15.4) 3 (20) 4 (18.2) 68 (88.3)
P-value 0.0001 0.007 0.01 0.001 0.0001
Amikacin 2 (8.3) 1 (7.7) 2 (13.3) 0 8 (10.4)
Gentamicin 1 (4.2) 0 2 (13.3) 2 (9.1) 34 (44.2)
P-value 0.009 0.02 0.0001
Tobramycin 3 (12.5) 1 (7.7) 0 3 (13.6) 36 (46.8)
P-value 0.006 0.0001
MDR 10 (41.7) 4 (30.8) 5 (33.3) 5 (22.7) 66 (85.7)
P-value 0.03 0.05 0.0001 0.0001
Resistance score (mean, median) 3.17, 2.50 3.54, 4 3, 1 2.77, 2 7, 7
ESBL phenotype 9 (37.5) 6 (46.2) 7 (46.7) 10 (45.5) 71 (92.2)
P-value 0.001 0.02 0.0001

Notes:

a

Comparison between each ST with all other STs combined. Bold values indicate significant associations. P-values in rows shown for differences that were statistically significant (P<0.05). Underlining indicates a negative association.

Abbreviations: MDR, multidrug resistance; ESBL, extended spectrum β-lactamase.